iTeos Therapeutics (NASDAQ:ITOS) PT Lowered to $32.00 at JPMorgan Chase & Co.

iTeos Therapeutics (NASDAQ:ITOS – Get Rating) had its target price reduced by JPMorgan Chase & Co. from $34.00 to $32.00 in a research note released on Thursday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Separately, Wedbush cut their price target on shares of iTeos Therapeutics from $45.00 to $33.00 and set an outperform rating for the company in a report on Thursday.

iTeos Therapeutics Stock Down 4.4 %

Shares of ITOS stock opened at $14.12 on Thursday. iTeos Therapeutics has a 12-month low of $13.81 and a 12-month high of $37.26. The company has a market capitalization of $504.37 million, a P/E ratio of 5.49 and a beta of 1.42. The firm has a 50-day moving average price of $18.81 and a 200 day moving average price of $19.40.

Hedge Funds Weigh In On iTeos Therapeutics

A number of institutional investors have recently modified their holdings of ITOS. Point72 Hong Kong Ltd bought a new position in shares of iTeos Therapeutics in the first quarter worth about $67,000. Quantbot Technologies LP bought a new position in shares of iTeos Therapeutics in the second quarter worth about $69,000. Mutual of America Capital Management LLC raised its stake in shares of iTeos Therapeutics by 17.4% in the second quarter. Mutual of America Capital Management LLC now owns 3,402 shares of the company’s stock worth $70,000 after acquiring an additional 505 shares during the last quarter. Ensign Peak Advisors Inc bought a new position in shares of iTeos Therapeutics in the first quarter worth about $73,000. Finally, Teachers Retirement System of The State of Kentucky bought a new position in shares of iTeos Therapeutics in the third quarter worth about $117,000.

iTeos Therapeutics Company Profile

(Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.